Who Paid My Doc
Gamifant
Drug Hematology
NDC 72171-505-01
General payments
$4,126,496
Research payments
$8,776,024
Through program year 2025, $4,126,496 in general payments and $8,776,024 in research payments were reported against Gamifant (Hematology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,185,716 | 1,902 |
| 2025 | Research | $1,507,292 | 84 |
| 2024 | General | $936,691 | 1,549 |
| 2024 | Research | $4,804,440 | 136 |
| 2023 | General | $795,477 | 1,299 |
| 2023 | Research | $1,098,633 | 138 |
| 2022 | General | $559,545 | 973 |
| 2022 | Research | $220,009 | 120 |
| 2021 | General | $442,707 | 526 |
| 2021 | Research | $705,223 | 187 |
| 2020 | General | $117,844 | 195 |
| 2020 | Research | $423,685 | 113 |
| 2019 | General | $88,515 | 230 |
| 2019 | Research | $16,743 | 3 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 60 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 44 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
6,674 general · 781 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.